Collaborations & Alliances

Genmab Achieves Janssen Milestone

Advances Phase II trial in follicular lymphoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has reached a $5 million milestone in its daratumumab collaboration with Janssen Biotech triggered by progress in the ongoing Phase II study (“Carina” LYM2001) in NHL.   The study evaluates daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). This milestone is related to progress in the arm of the study treating patients with FL.   “The daratumumab study in NHL is now ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters